CONCLUSION The use of oral hypoglycemic drugs is approximate stable in recent 3 years.
结论我院近3年口服降血糖药物应用基本稳定。
OBJECTIVE To provide the information for rational administer of oral hypoglycemic drugs.
目的为临床合理应用口服降血糖药提供信息。
At the same time two groups of patients had oral hypoglycemic drugs and insulin therapy.
同时两组患者均口服降糖药物和胰岛素治疗。
OBJECTIVE: To evaluate the status quo and developmental trend of the use of oral hypoglycemic drugs in guangdong area.
前言： 目的：评价广东地区口服降糖药应用现状及趋势。
RESULTS the varieties quantities and sales volumes of hypoglycemic drugs increased year by year, while oral hypoglycemic drugs were the leading drugs in our hospital.
结果我院降血糖药品种、数量及销售金额逐年增长，其中以口服降血糖药为主导用药。
Objective: To introduce the types and main roles of oral hypoglycemic drugs, emphasizing on the action mechanism and developmental trends of insulin sensitizing agent.
目的：介绍口服降糖药物的种类和主要作用，重点介绍胰岛素抵抗改善药物的作用机制和开发动态。
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obese type 2 diabetic mellitus(T2DM).
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
Insulin secretagogues presently is not only a kind of major oral hypoglycemic drugs but also the first-line treatment for non-obese and obese type 2 diabetic mellitus(T2DM).
胰岛素促泌剂是目前治疗2型糖尿病的一类主要口服降糖药，是非肥胖及部分肥胖2型糖尿病的一线治疗药物。
应用推荐